Clinical Trial

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer: (VANDAAM)" that had high risk Decipher test results (Decipher score \>0.45). Patients with a high genomic classifier (GC) score at diagnosis will be approached for formal consenting for PSMA-PET imaging at 2 years post treatment.
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2018-04-05; most recent amendment 2026-02-26.
Status change: Suspended → Recruiting 2021-07-26
Status change: Recruiting → Suspended 2020-05-22
Status change: Not Yet Recruiting → Recruiting 2019-10-17
Trial Details
NCT Number NCT03495427
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Progenics Pharmaceuticals, Inc.
Conditions Prostate Cancer, Recurrent Prostate Cancer
Enrollment 60 participants
Start Date 2019-12-18
Primary Completion 2029-02 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-02